It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Recent studies have shown that microRNAs (miRNAs) play a role as regulators of neurodevelopment by modulating gene expression. Altered miRNA expression has been reported in various psychiatric disorders, including schizophrenia. However, the changes in the miRNA expression profile that occur during the initial stage of schizophrenia have not been fully investigated. To explore the global alterations in miRNA expression profiles that may be associated with the onset of schizophrenia, we first profiled miRNA expression in plasma from 17 patients with first-episode schizophrenia and 17 healthy controls using microarray analysis. Among the miRNAs that showed robust changes, the elevated expression of has-miR-223-3p (miR-223) was validated via quantitative reverse transcription-polymerase chain reaction (qRT-PCR) using another independent sample set of 21 schizophrenia patients and 21 controls. To identify the putative targets of miR-223, we conducted a genome-wide gene expression analysis in neuronally differentiated SK-N-SH cells with stable miR-223 overexpression and an in silico analysis. We found that the mRNA expression levels of four genes related to the cytoskeleton or cell migration were significantly downregulated in miR-223-overexpressing cells, possibly due to interactions with miR-223. The in silico analysis suggested the presence of miR-223 target sites in these four genes. Lastly, a luciferase assay confirmed that miR-223 directly interacted with the 3′ untranslated regions (UTRs) of all four genes. Our results reveal an increase in miR-223 in plasma during both the first episode and the later stage of schizophrenia, which may affect the expression of cell migration-related genes targeted by miR-223.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan; International Research Center for Neurointelligence, The University of Tokyo, Tokyo, Japan
2 Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
3 Department of Child Neuropsychiatry, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
4 Department of Psychiatry, Fukui Kinen Hospital, Miura City, Kanagawa, Japan
5 Department of Mental Health, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
6 Department of Mental Health, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan; Department of Public Health Nursing, Graduate School of Nursing Science, St. Luke’s International University, Tokyo, Japan
7 Center for Human and Social Sciences, College of Liberal Arts and Sciences, Kitasato University, Sagamihara City, Kanagawa, Japan
8 Department of Health Economics and Epidemiology Research, School of Public Health, the University of Tokyo, Tokyo, Japan
9 Department of Molecular Brain Science, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Japan